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Philadelphia, PA, United States, 10 Pediatric Endocrinology, Children's Health of Orange County
(CHOC) Children’s Hospital, Orange, CA, United States, 11 Division of Endocrinology, Nemours
Children’s Health, Jacksonville, FL, United States, 12 The Saban Research Institute, Children’s
Hospital Los Angeles, Los Angeles, CA, United States, 13 Keck School of Medicine, University of
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Noonan, Turner, and Prader-Willi syndromes are classical genetic disorders
that are marked by short stature. Each disorder has been recognized for several
decades and is backed by extensive published literature describing its features,
genetic origins, and optimal treatment strategies. These disorders are
accompanied by a multitude of comorbidities, including cardiovascular
issues, endocrinopathies, and infertility. Diagnostic delays, syndromeassociated comorbidities, and inefﬁcient communication among the
members of a patient’s health care team can affect a patient’s well-being
from birth through adulthood. Insufﬁcient information is available to help
patients and their multidisciplinary team of providers transition from pediatric
to adult health care systems. The aim of this review is to summarize the clinical
features and genetics associated with each syndrome, describe best practices
for diagnosis and treatment, and emphasize the importance of multidisciplinary
teams and appropriate care plans for the pediatric to adult health
care transition.
KEYWORDS

Noonan syndrome, Turner syndrome, Prader-Willi syndrome, short stature, growth
hormone, genetics
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Introduction

Features

Noonan, Turner, and Prader-Willi syndromes are classical
genetic conditions that share poor linear growth as a common
feature. While the three syndromes share some characteristic
features, each represents a vastly different genetic defect (sex
chromosome aneuploidy, autosomal dominant mutation, and
errors in genomic imprinting). These syndromes are all
accompanied by comorbidities that require proper monitoring
and treatment throughout a patient’s lifetime. Each syndrome is
well-recognized and is backed by extensive published literature
describing their features, genetic origins, and optimal treatment
strategies. However, treatment of individuals may be
complicated by diagnostic delays and lack of communication
among healthcare specialists. Furthermore, insufﬁcient
information is available on natural history to guide the patient
with Noonan, Turner, or Prader-Willi syndrome from infancy
into adulthood.
This review delineates the clinical features and genetics
associated with each disorder, details diagnosis and treatment
methods, and discusses the importance of multidisciplinary care
and proper transition from pediatric to adult health
care systems.

Individuals with NS display several characteristic traits,
including distinctive craniofacial features, growth abnormalities,
cardiovascular and skeletal anomalies, cryptorchidism in males,
bleeding disorders, and other comorbidities (1).
The distinctive facial characteristics associated with NS are
prominent in infancy, change as the child ages, and become
more subtle in adulthood (7). The head is large with a tall
forehead and the eyes are prominent and widely spaced
(hypertelorism), sometimes with unilateral or bilateral ptosis
(2). Epicanthal folds and downward-slanting palpebral
ﬁssures are also somewhat common (8). As an individual
with NS ages, the eyes become less prominent, the hair may
become curly or wooly, and the face lengthens into a
triangular shape (7). Other notable facial features can be
found in Table 1.
About 80% of individuals with NS will exhibit short stature
(Figures 1A, B) (1, 43, 44). Although abnormal growth is a
characteristic feature of NS, some individuals will display normal
growth patterns and adult height. Birth weight and length tend
to be within a normal range (45, 46); however, there is a
subsequent deceleration of height and weight to -2.0 SD or
less (43, 44). Mean adult heights range from -2.3 to -2.5 SD for
males and -2.1 to -2.2 SD for females based on height references
from four different patient populations (43, 44, 47, 48). Puberty
is commonly but not universally delayed in both sexes and is
associated with a reduced growth spurt (1, 8). There is a mean
bone age delay of about two years, and reports of growth
hormone (GH) secretory dynamics are inconsistent; various
studies have reported GH deﬁciency (37% to 45% of
individuals), neurosecretory dysfunction, and even normal GH
secretion (1). Insulin-like growth factor I (IGF-I) concentrations
are typically low and are signiﬁcantly lower in individuals with
PTPN11 gene variants (1).
Most patients with NS display cardiac abnormalities
(Table 1), including congenital heart disease (CHD) in about
80% of patients and hypertrophic cardiomyopathy (HCM) in
about 20% of patients (16, 49). A broad spectrum of right- and
left-sided cardiac lesions have been described in this condition.
Pulmonary stenosis (PS), the most common manifestation of
CHD, is present in about 40% of patients. Approximately 60% of
PS cases are mild, with 10% presenting as moderate and 30%
presenting as severe; 25% to 35% of patients with PS display a
dysplastic valve (1, 16). Mild PS typically does not progress
beyond early infancy, may resolve on its own within the ﬁrst few
months of life, and requires no intervention (50, 51). Beyond the
age of 6 months, mild PS is often characterized as a static lesion
(51). Fifty percent of patients with NS display an unusual
electrocardiographic pattern, even in the absence of any other
cardiac lesion (1).
Most individuals display superior pectus carinatum and
inferior pectus excavatum, while 50% may display joint

Noonan syndrome
Noonan syndrome (NS) is a congenital genetic disorder that
occurs in 1 in every 1000 to 2500 live births (1–3). It is caused by
germline gain-of-function RAS/MAPK (mitogen-activated
protein kinase) pathway variants and is therefore classiﬁed as
a RASopathy (4). RAS/MAPK signaling is typically involved in
the cell cycle, proliferation, differentiation, growth, and
senescence, with alterations in this pathway having signiﬁcant
effects on developmental processes (5). NS-causing gene variants
are typically inherited in an autosomal dominant fashion,
although other patterns, including de novo and autosomal
recessive patterns, have been observed (3, 6).

Abbreviations: ADHD, attention deﬁcit hyperactivity disorder; ASD, autism
spectrum disorder; CFC, cardiofaciocutaneous; CHD, congenital heart
disease; FDA, Food and Drug Administration; GH, growth hormone;
HCM, hypertrophic cardiomyopathy; IGF-I, insulin-like growth factor I;
LAGH, long-acting growth hormone; MAPK, mitogen-activated protein
kinase; MRA, magnetic resonance angiography; MRI, magnetic resonance
imaging; NBS, newborn screening; NF1, neuroﬁbromatosis type 1; NORD,
National Organization for Rare Disorders; NS, Noonan syndrome; NS/MPD,
Noonan syndrome/myeloproliferative disorder; PS, pulmonary stenosis;
PWS, Prader-Willi syndrome; SDS, standard deviation score; TRAQ,
Transition Readiness Assessment Questionnaire; TS, Turner syndrome;
UPD, uniparental disomy.
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TABLE 1 Clinical features and comorbidities associated with Noonan, Turner, and Prader-Willi syndromes.

Fetal Characteristics
Noonan

Turner

Prader-Willi

• Polyhydramnios

•Lymphedema (97%)

•Hypotonia (94%)

•Pleural effusion

•Polyhydramnios

•Reduced fetal movement (88%)

•Increased nuchal translucency

•Pleural effusion

•Polyhydramnios (34%)

•Cystic hygroma

•Increased nuchal translucency

•Hydrothorax

•Cystic hygroma
•Oligohydramnios
•Left-sided obstructive cardiac anomalies

Facial Features
Noonan

Prader-Willi

Turner

Head and Neck

Head and Neck

Head and Neck

•Low-set, posteriorly rotated ears (90%)

•Wide neck (40%)

•Narrow forehead (75%)

•Low posterior hairline (68%)

•Low posterior hairline (40%)

•Elongated skull

•Short neck (elongated in adulthood) with excess skin/ •External ear abnormalities, including low-set ears and protruding •Small, upturned nose
webbing (55%)
pinnae (34%)
•Curly or wooly hair in adulthood (33%)

•Webbed neck (25%)

•Wispy hair (10%)
•Large head with a tall forehead and small face
•Short, broad nose with a depressed root and full tip

Eyes
•Ophthalmologic problems (94%)
Strabismus (48%-63%)
Amblyopia (33%)
Refractive errors
Anterior segment changes
•Down-slanted palpebral ﬁssures with epicanthal folds
(68%)

Eyes

Eyes

•Strabismus (25%-35%)
•Ptosis (16%)
•Epicanthal folds (11%)
•Hypertelorism (3%)

•Almond-shaped, elongated eyes (75%)
•Strabismus (60%-70%)
•Up-slanting palpebral ﬁssures

•Down-slanted palpebral ﬁssures

•Ptosis (42%)
•Hypertelorism
•Telecanthus

Mouth

Mouth

Mouth

•Full upper lip with a deeply grooved philtrum (95%)

•Micrognathia (60%)

•High-arched palate

•High-arched palate (>55%)

•High-arched, narrow palate (35%)

•Micrognathia
•Downward-turned corners of mouth

•Micrognathia (33%-43%)

•Thin upper lip
•Enamel hypoplasia

Growth Characteristics
Noonan

Turner

Prader-Willi

•Short stature (~80%)

•Short stature (up to 95%)

•GH deﬁciency (40%-100%)

•Feeding problems/poor suck (76%)

•GH resistance

•Short stature (90%)
•Feeding problems/poor suck

•GH deﬁciency (37%-45%)
•GH resistance

Cardiovascular
Noonan

Turner

•CHD (80%)

•Elongated transverse aortic arch (50%)

•Bleeding disorders (30%-65%)

•Hypertension (50%)

•Intrinsic pathway abnormalities (50%)

•Aortic dilation/aneurysm(3%-42%)

Prader-Willi
•Right-sided heart failure

(Continued)
(Continued)
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TABLE 1 Continued

Cardiovascular
Noonan

Turner

•Abnormal electrocardiographic pattern (50%)

•Prolonged QT interval (21%-36%)

•PS (40%)

•Bicuspid aortic valve (15%-30%)

Prader-Willi

•Factor deﬁciencies (FVIII, FXI, FXII), platelet defects •Aortic coarctation (7%-18%)
(33%)
•Aortic valve stenosis (4%-16%)
•HCM (20%)
•Mitral valve regurgitation or prolapse (1%-9%)
•Atrioventricular canal defects (15%)
•Stroke
•Atrial septal defect (6%-10%)

•Coronary artery disease

•Left-sided obstructive lesions

•Hypoplastic left heart syndrome
•Aortic insufﬁciency
•Increased myocardial workload
•Arrhythmias

Reproductive
Noonan

Turner

•Cryptorchidism (80% of males)

•Primary ovarian insufﬁciency (95%-98%)

•Pubertal delay

•Pubertal delay (or absence) (85%)

•Gonadal dysfunction in males; normal fertility in females •Hypergonadotropic hypogonadism

Prader-Willi
•Central and/or primary hypogonadism
(100%)
•Cryptorchidism (80%-100% of males)
•Pubertal delay (or absence)

Renal and Endocrine
Noonan

Turner

Prader-Willi

•Horseshoe kidney

•Autoimmune hypothyroidism (24%)

•Central adrenal insufﬁciency (10%)

•Duplicated collecting system

•Duplicated collecting system (5%-15%)

•Central hypothyroidism (10%)

•Renal pelvis dilation

•Horseshoe kidney (10%)

•Solitary kidney

•Ectopic kidney (<1%)
•Elevated gonadotropins
•Kidney hypoplasia

Metabolic
Noonan

Turner

Prader-Willi

•Glucose intolerance (15%-50%)

•Obesity (94%-100%)

•Obesity (15%)

•Metabolic syndrome (38%)

•Type II diabetes (10%)

•Type II diabetes (25%)

•Metabolic syndrome

•Reduced glucose tolerance

•Reduced insulin sensitivity

•Insulin resistance

•Gluten-sensitive enteropathy (celiac disease)

Musculoskeletal
Noonan

Turner

Prader-Willi

•Inferior pectus excavatum (95%)

•Kyphosis (40%-75%)

•Scoliosis (40%)

•Superior pectus carinatum (95%)

•Scoliosis (12%-59%)

•Hip dysplasia (10%-20%)

•Joint hypermobility (50%)

•Cubitus valgus (50%)

•Osteopenia

•Cubitus valgus (50%)

•Short 4th metacarpal (35%)

•Osteoporosis

•Scoliosis (10%-15%)

•Genu valgum (35%)

•Small hands and feet

•Talipes equinovarus (10%-15%)

•Pectus excavatum (20%)

•Cervical spine fusion (2%)

•Osteoporosis

•Radio-ulnar synostosis (2%)

•Hip dysplasia
(Continued)
(Continued)
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TABLE 1 Continued

Musculoskeletal
Noonan

Turner

Prader-Willi

•Radio-ulnar synostosis (Madelung deformity)

•Osteopenia
•Kyphosis
•Spina biﬁda
•Vertebral and rib abnormalities
•Genu valgum

Neurocognitive Characteristics
Noonan

Turner

Prader-Willi

•ADHD (40%-50%)/ASD (30%)

•Behavioral problems (25%)

•Behavioral problems (90%)

•Learning difﬁculties/intellectual disability (10%-40%)

•ADHD (24%)/ASD

•Compulsive tendencies (60%)

•Behavioral problems

•Learning difﬁculties (23%)/intellectual disability (10%)

•Neurocognitive issues

•Neurocognitive issues

•Learning difﬁculties/intellectual
disability (40%)
•ASD (12%-41%)

•Memory deﬁcits

•Neurocognitive issues

Other Clinical Features
Noonan

Turner

Prader-Willi

•Splenomegaly (52%)

•Elevated liver enzymes (transaminitis) (50%-80%)

•Seizures (10%-20%)

•Hearing loss (25%)

•Sensorineural hearing loss (60% of adults)

•Sleep apnea

•Disordered lymphatic development (20%)

•Widely-spaced nipples (30%)

•Seizures (10%-13%)

•Nail hypoplasia (10%)

•Chylothorax (10%)

•Celiac disease (4%-6%)

•Peripheral lymphedema (5%-10%)

•Inﬂammatory bowel disease (2%-3%)

•Widely-spaced nipples

•Increased cancer rates

•Increased cancer rates

•Lymphatic hypoplasia or aplasia

•Lymphangiectasis

•NAFLD/hepatosteatosis

•Abnormal lymphatic vessels

References
Noonan

Turner

Prader-Willi

(19–28)

(29–42)

(1, 2, 8–18)

ADHD, attention deﬁcit hyperactivity disorder; ASD, autism spectrum disorder; CHD, congenital heart disease; GH, growth hormone; HCM, hypertrophic cardiomyopathy; NAFLD,
nonalcoholic fatty liver disease; PS, pulmonary stenosis.

be noted that these defects are not necessarily correlated with the
bleeding phenotype of patients with NS, and the explanation for
bleeding risk remains incompletely understood. Recently, a
study of patients with NS and NS with multiple lentigines and
two PTPN11 variant-driven NS mouse models revealed that
platelet signaling defects are involved with NS-associated
thrombopathy (55), providing insight into the bleeding effects
of gain and loss-of-function SHP2 variants.

hypermobility or hypotonia (1, 8). Less common skeletal issues
can be found in Table 1.
Unilateral and bilateral cryptorchidism have been reported
in about 80% of male patients (1, 2, 8).
Disordered bleeding has been reported in patients with NS
and can range from mild (easy bruising, menorrhagia) to severe
(signiﬁcant bleeding during surgical procedures) (1, 8). Several
coagulation factor deﬁciencies (typically factors VIII, XI, or XII),
platelet dysfunction, and thrombocytopenia have been described
in individuals with NS (1, 16, 52–54). About 50% of individuals
with NS have abnormalities in the intrinsic coagulation pathway
and 65% display abnormal bruising or bleeding tendencies (2).
Variants in the PTPN11 gene, which encodes the SHP2 protein,
may be particularly associated with bleeding problems. It should
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A

B

FIGURE 1

Growth curves for patients with NS. Heights (mean and -1 SD) of males (A) and females (B) with NS are shown with solid lines and overlaid on
the normative percentile ranges, with normative mean to +1 SD in dark shading and normative mean to -1 SD in light shading. Also depicted are
the heights of 35 males and 30 females with NS at the start of GH treatment (open symbols) and at ﬁnal height (solid symbols). Adapted from
Romano AA et al. J Clin Endocrinol Metab 2009;94(7):2338-2344. GH, growth hormone; NS, Noonan syndrome.

skeletal anomalies, cryptorchidism in males, and bleeding
disorders—there are many other comorbidities. These
comorbidities are variable and may depend on gene variant
associations (Table 2). No phenotype is exclusive to a single
variant; however, some phenotypes may be more common in
association with a particular genotype, as discussed below.

Lymphatic
Approximately 20% of patients with NS have manifestations
of disordered lymphatic development. This most frequently
presents as peripheral lymphedema in infancy and tends to
resolve within the ﬁrst few years of life, although it can recur in
adolescence or adulthood. Lymphatic abnormalities can also
present as lymphangiectasis or development of abnormal
lymphatic vessels, particularly in the thoracic region (1). Some
individuals with NS may display postoperative or spontaneous
chylothorax (approximately 10% of cases) (16, 87, 88).

Gastrointestinal
Feeding problems have been described in up to 76% of
infants with NS and appear to be associated with delayed
developmental milestones and worse long-term outcomes (8,
84). About 24% may require tube feeding in early life. Most
often, feeding problems are attributable to poor suck,
gastroesophageal reﬂux, and/or delayed gastric emptying and
typically resolve by 1 to 2 years of age (8).

Hematologic/oncologic
Besides disordered bleeding, hematologic comorbidities
include splenomegaly, which may cause thrombocytopenia and
is seen by ultrasound in up to 52% of individuals with NS (89).
Splenomegaly may be isolated, associated with hepatomegaly,
and/or caused by NS/myeloproliferative disorder (NS/MPD).
NS/MPD, typically seen in infants, is characterized by
leukocytosis with monocytosis, thrombocytopenia, and
hepatosplenomegaly. The clinical appearance of NS/MPD is
similar to that of juvenile myelomonocytic leukemia, but
infants with NS/MPD typically have a favorable prognosis and
will remain stable or improve without speciﬁc therapy. Certain
studies have suggested that patients with NS display elevated
rates of malignancy due to hyperactivated RAS/MAPK signaling.
Several case studies have reported speciﬁc malignancies,

Genitourinary
Renal issues (Table 1) occur in a minority (approximately
10%) of patients with NS and are typically of little clinical
signiﬁcance. Gonadal dysfunction in males with NS may be
due to altered spermatogenesis (speciﬁcally Sertoli cell
dysfunction) rather than cryptorchidism (1, 11, 85). Males
with NS have reduced fertility; however, the exact frequency
with which this occurs remains unknown (3, 86). Females
exhibit normal fertility rates (1).
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TABLE 2 Genotypic-phenotypic correlations in NS.

Genes
involved

Frequency of
cases

PTPN11

50%

Most common features

References

•Short stature

(1, 2, 9, 11, 16, 56–63)

•Chest deformity
•Characteristic facial features
•PS (45%-70% of patients)
•Atrial septal defects
•Less likely to have HCM
•Hematologic abnormalities
•Low IGF-I
•No or mild cognitive impairment (especially in association with N308S variant)
•Development of malignancies
•Potentially elevated risk of hearing loss
•More common in familial versus sporadic NS cases
•Cryptorchidism
SOS1

20%

•CFC syndrome–like skin ﬁndings (keratosis pilaris, sparse hair, curly hair, sparse eyebrows)
•Less likely to have short stature

(1, 2, 11, 16, 58, 59, 63–
65)

•No or mild cognitive impairment
•Ectodermal abnormalities
•PS (~83% of patients)
•Giant cell lesions
LZTR1

8%

•Predisposition to schwannomas

KRAS

5%

•Severe learning issues and developmental delays

(11, 66)
(11, 67–69)

•HCM
•Possibly craniosynostosis
RIT1

4%-9%

•Perinatal abnormalities (e.g., polyhydramnios)

(11, 16, 63, 70–75)

•High birth weight
•Relative macrocephaly
•CHD (94%)
HCM (71%)
PS (65%)
•Increased ectodermal ﬁndings (including curly hair, hyperpigmentation, wrinkled palms and
soles)
•Less likely to have intellectual disability
•Less likely to have short stature and chest deformities
SOS2

4%

•Ectodermal defects

(11, 63)

•Infrequent short stature
•Lymphatic abnormalities (>50%)
RAF1

3%-17%

•HCM (95%)

(11, 16, 76)

BRAF

2%

•Short stature

(11, 77)

•Dysmorphic facial features
•Skeletal anomalies
•Hypotonia
•Mild to moderate cognitive defects
MAP2K1

<2%

•Increased ectodermal ﬁndings

(11, 72, 78)

•Overall milder phenotype
NRAS

<1%

•Variable

MRAS

<1%

•Increased prevalence of HCM

(63, 81)

A2ML1

<1%

•Developmental delays

(11, 82)

SHOC2

NR

•Loose anagen hair

(11, 79, 80)

(1, 11, 83)

•Mitral valve and cardiac septal defects
(Continued)
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TABLE 2 Continued

Genes
involved

Frequency of
cases

Most common features

References

•GH deﬁciency
•Ectodermal abnormalities with darkly pigmented ichthyotic skin
•Hypernasal voice
•Developmental issues with hyperactivity
A2ML1, a2-macroglobulin-like-1; BRAF, V-Raf murine sarcoma viral oncogene homolog B1; CFC, cardiofaciocutaneous; CHD, congenital heart disease; GH, growth hormone; HCM,
hypertrophic cardiomyopathy; IGF-I, insulin-like growth factor I; KRAS, kirsten rat sarcoma viral oncogene homolog; LZTR1, leucine-zipper-like transcription regulator 1; MAP2K1,
mitogen-activated protein kinase kinase 1; MRAS, muscle RAS oncogene homolog; NR, not reported; NRAS, neuroblastoma rat sarcoma viral oncogene homolog; NS, Noonan syndrome;
PS, pulmonary stenosis; PTPN11, protein-tyrosine phosphatase, non-receptor type 11; RAF1, v-raf-1 murine leukemia viral oncogene homolog 1; RIT1, Ric-like protein without Caax motif
1; SHOC2, SHOC2 leucine-rich repeat scaffold protein; SOS1, Son of Sevenless homolog 1; SOS2, Son of Sevenless homolog 2.

including gliomas, dysembryoplastic neuroepithelial tumors,
and hematologic malignancies in patients with NS (2, 90–92).
A Dutch study demonstrated a link between NS-associated
PTPN11 variants and increased cancer rates (93), while a
recent German study reported signiﬁcantly increased
childhood cancer rates in patients with NS regardless of the
underlying variant (94).

although they may not always meet the stringent criteria
necessary for an ofﬁcial diagnosis (12, 13, 15, 17, 97).
Language impairments are more frequent in children with NS
and are associated with a higher risk of reading and spelling
difﬁculties (98).
Those with NS may also experience poor body image, selfesteem issues, anxiety, and depression (1, 17). It has been
suggested that some of these social issues may be linked to
poor verbal development (95). Even into adulthood, individuals
with NS may have difﬁculty maintaining satisfying social
relationships and may report low-to-moderate levels of overall
life satisfaction (17).

Neurologic/cognitive/psychological
NS-associated neurologic, cognitive, and psychological/
behavioral issues are highly variable in frequency and severity
and can signiﬁcantly affect quality of life (1). Motor milestones
are often delayed, with one study reporting that, on average,
patients with NS sat unassisted at 10 months, walked at 21
months, and spoke in two-word sentences at 31 months (1, 8).
Children with NS can have problems with verbal articulation
and may beneﬁt from early intervention with speech therapy
(95, 96).
Individuals with NS typically display normal levels of
intelligence, although 10% to 40% of patients may require
some level of special education (1, 15, 18). The heterogeneity
in cognitive abilities among individuals with NS may be ascribed
to differences in the underlying molecular variant responsible for
the condition (59) (Table 2).
Structural brain abnormalities are infrequent but may
include hydrocephalus and Arnold-Chiari malformation type I
(1). Patients with NS also appear to have smaller caudate,
putamen, and pallidum volumes compared with controls (15).
Recurrent seizures have been reported in 13% of patients (8).
Sensorineural issues may also be present, including ocular
problems (94% of patients), hearing loss, and peripheral
neuropathy (1, 2, 8).
Psychological and psychosocial issues associated with NS
may include increased clumsiness, stubbornness, and irritability
and weaker social skills compared with unaffected siblings (1,
97). Children with RASopathies, particularly NS, often display
symptoms associated with attention deﬁcit hyperactivity
disorder (ADHD) and autism spectrum disorder (ASD),
including inattention, poor impulse control, and hyperactivity,
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Diagnosis
Early diagnosis is crucial for individuals with NS because
each patient will require a unique treatment plan and will have a
different prognosis and risk of recurrence (1). These authors
suggest that screening for NS be added to newborn screening
(NBS) programs to ensure rapid and early diagnosis.
Prenatally, NS may be suspected based on polyhydramnios,
abnormalities of the lymphatic system (e.g., increased nuchal
translucency, cystic hygroma, pleural or pericardial effusion,
ascites, hydrops fetalis), and cardiac and/or renal
abnormalities. An abnormal maternal blood triple screen test
(for alpha-fetoprotein, human chorionic gonadotropin, and
unconjugated estriol) may also be an indicator of NS (3).
The diagnosis can be corroborated using fetal ultrasound
and echocardiography techniques (69) and conﬁrmed by
prenatal and/or postnatal molecular testing (see below). After
birth, NS may be suspected based on characteristic facial
features or the presence of bleeding or cardiac abnormalities
(Figure 2) (3). Scoring systems have also been proposed to aid in
the clinical diagnosis of NS (10). Diagnoses based on clinical
features can be conﬁrmed by genetic testing in up to 70% of
cases (3).
Molecular genetic testing has identiﬁed at least 13 genes with
pathogenic variants that contribute to NS (Table 2) (63). Genetic
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Development Group1, Romano and colleagues (1), National
Organization for Rare Disorders (NORD)2, and BMJ Best
Practice3. Despite their limitations (all lack a standardized
consensus development process), they have been clinically
useful and have illustrated the need for further studies,
molecular diagnoses, and data collection. Patient support
groups for individuals with NS include the Noonan Syndrome
Foundation, RASopathies Network, NORD, the Human Growth
Foundation, and the Magic Foundation. Improved education of
providers (particularly pediatricians) is critical, as patients with
NS will need referral to multiple care specialists to address the
many comorbidities that accompany the disorder.

testing approaches can include the use of a multigene panel,
serial single gene testing, and/or more comprehensive genomic
testing with deletion/duplication analysis (1). In general, a
multigene panel is the test of choice. If that is not feasible,
serial single gene testing beginning with PTPN11 could be
considered, because 50% of individuals with NS display
PTPN11 variants. If either of these approaches fails to conﬁrm
a diagnosis in an individual with NS features, more
comprehensive genomic testing may be considered when
available. However, a limitation of genetic testing is that
current technologies reveal no speciﬁc molecular defect in
roughly 30% of NS cases. Availability of and approval (from
both families and insurance carriers) for such testing can also be
a barrier to diagnosis.
The characteristic features of NS are often similar to those of
Turner syndrome (TS) (discussed in more detail below).
However, a few key features distinguish these two syndromes.
Most notably, TS only affects females, while NS affects males and
females equally (4). Additionally, individuals with TS often
display primary ovarian insufﬁciency, while fertility does not
seem to be affected in girls with NS. Finally, NS is typically
caused by a RAS/MAPK pathway gene variant, while TS is
characterized by the complete or partial loss of the second X
chromosome in females (1).
Several other syndromes, including cardiofaciocutaneous
(CFC) syndrome, NS with multiple lentigines,
neuroﬁbromatosis type 1 (NF1), and Costello syndrome also
show signiﬁcant phenotypic similarities to NS (1). These
syndromes all result from RAS/MAPK signaling pathway
variants and are classiﬁed as RASopathies. Many can be
distinguished based on their clinical features. For example,
individuals with CFC syndrome tend to have more severe facial
features, feeding difﬁculties, and intellectual difﬁculties than those
with NS. Costello syndrome can be distinguished by its associated
hair loss, moderate intellectual difﬁculties, and increased
pigmentation that develops with age (1). Several syndromes can
be genetically differentiated from NS (2); for example, Costello
syndrome is caused by HRAS variants not observed in NS (1),
while NF1 is characterized by variants in the neuroﬁbromin 1
(NF1) gene (5). A combined neuroﬁbromatosis-Noonan
syndrome, in which affected individuals display symptoms of
both NF1 (especially café -au-lait spots) and NS, has also been
observed. Genetic studies have revealed that neuroﬁbromatosisNoonan syndrome may result from speciﬁc NF1 variants,
including the p.R1809C variant or in rare instances from cooccurring NF1 and PTPN11 variants (99–101).
Because NS is such a genetically and phenotypically
heterogeneous disease, its identiﬁcation, diagnosis, and
management can be challenging. Key advances in improving
the diagnosis and care of individuals with NS include the
establishment of diagnostic and management guidelines and
patient support groups. The current published guidelines
include those from: DYSCERNE Noonan Syndrome Guideline
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Treatment
Appropriate evaluations should be conducted at the time of
diagnosis, as recommended in previous guidelines, to identify
associated comorbidities (1, 2). Treatment of most NSassociated comorbidities does not differ from treatment of the
same conditions in unaffected individuals. Treatments for the
more common NS abnormalities are described below and
include some NS-speciﬁc treatment considerations and
differences in approach.

Growth/puberty
Children with NS and growth failure that cannot be
explained by another comorbidity should have their nutrition
optimized and baseline laboratory assessments performed.
Puberty is often delayed in individuals with NS and may need
to be induced, but induction timing should be carefully
considered to avoid negatively impacting height outcomes (1,
62). Patients should be referred to a pediatric endocrinologist for
management of pubertal issues and growth failure and
consideration for GH therapy. GH therapy has been approved
by the Food and Drug Administration (FDA) for use in NS since
2007 and is now licensed for use in Switzerland, South Korea,
Israel, Brazil, Japan, and Europe (2).
Early initiation of GH therapy for NS-associated short
stature can lead to signiﬁcant short- and long-term increases
in height velocity, height standard deviation score (SDS), and
adult height (Table 3 and Figures 1A, B) (45, 62, 102, 110–112).
Earlier initiation, longer duration of therapy, and increased
height SDS at the time of treatment initiation are all positive
predictors of response to GH treatment (110–113). Additionally,
there is no difference in response to GH therapy between those

1

https://rasopathiesnet.org/wp-content/uploads/2014/01/265_

Noonan_Guidelines.pdf.
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2

https://rarediseases.org/rare-diseases/noonan-syndrome/.

3

https://bestpractice.bmj.com/topics/en-us/1193.
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FIGURE 2

Genetic testing ﬂowchart for NS. NS is typically diagnosed based on the observation of features such as craniofacial dysmorphism and facial
characteristics. Other RASopathies, including NF1 and Costello syndrome, exhibit similar phenotypes to that of NS and can be distinguished
using genetic testing approaches. However, a limitation of genetic testing is that approximately 30% of NS cases are not attributable to a known
gene variant. BRAF, V-Raf murine sarcoma viral oncogene homolog B1; CFC, cardiofaciocutaneous; HRAS, Harvey rat sarcoma viral oncogene
homolog; KRAS, Kirsten rat sarcoma viral oncogene homolog; MAP2K1, mitogen-activated protein kinase kinase 1; MAP2K2, mitogen-activated
protein kinase kinase 2; NF1, neuroﬁbromatosis type 1; NS, Noonan syndrome; NSML, Noonan syndrome with multiple lentigines; PTPN11,
protein-tyrosine phosphatase, non-receptor type 11, RAF1, v-raf-1 murine leukemia viral oncogene homolog 1; SHOC2, SHOC2 leucine-rich
repeat scaffold protein; SOS1, Son of Sevenless homolog 1.

individuals with NS (1, 45, 46, 62, 112). Further studies are
needed to substantiate the continued safety of GH use in NS with
respect to cardiac risks. At this time, for individuals with a
clinical diagnosis of NS for whom GH therapy is indicated and
who have cardiomyopathy, baseline and regular ultrasound
examinations should be performed. Those with severe
cardiomyopathy should not be treated with GH (115).
Because of an increased risk of cancer in individuals with NS,
there are speciﬁc risk considerations for all patients with a
clinical diagnosis of NS for whom GH therapy is indicated.
Patients and caregivers should be informed that the risk of
developing cancer in association with GH treatment has not
been adequately studied (116). Studies reporting increased
malignancy rates with GH treatment are sparse and tend to
include only small patient cohorts (62). Primary brain tumors
appear to be increased in individuals with NS (92) and therefore

who are GH-deﬁcient and those who are GH-sufﬁcient (110,
114). IGF-I concentrations are low in patients with NS but
increase upon initiation of GH treatment. It is suggested that
IGF-I levels be carefully monitored during GH dose escalation
and maintained between 0 and +2 SDS (46).
Despite initial concerns regarding GH resistance or poor
response in patients with PTPN11 variants, longer-term studies
have shown similar growth responses and adult height outcomes
in individuals with and without PTPN11 variants (9, 103).
Further studies are needed to clarify the role of the different
RAS/MAPK pathway aberrations in GH responsiveness.
Several concerns have been raised about the safety of GH in
individuals with NS, particularly in those with cardiac-related
comorbidities. However, multiple studies have revealed no
changes in cardiac parameters, including left ventricular wall
thickness, and few cardiac-related adverse events in GH-treated

TABLE 3 Impact of GH on height in Noonan, Turner, and Prader-Willi syndromes.

Noonan

Turner

Prader-Willi

FDA-approved GH dose

≤66 mcg/kg/d

FDA approval year

2007

1996

2000

Average untreated adult height

163 cm (males)
153 cm (females)

143 cm

155 cm (males)
147 cm (females)

GH-treated adult height

Improves ﬁnal height by
9-13 cm

Improves ﬁnal height by 5-8 cm

Improves ﬁnal height by 18 cm (females), 20 cm (males)

Recommended age at treatment
initiation

Before puberty‡

Recommended by 4-6 years, as early as
9 months

Approved for individuals ≥2 years old, recommended as early
as 4-6 months

References

(1, 102, 103)

(25, 104–107)

(33, 39, 108, 109)

34-50 mcg/kg/d*,†

47-67 mcg/kg/d

*It is recommended that GH dosing in obese patients be based on the ideal (nonobese) body weight (108). †Up to 1 mg/m2/day in children, with subsequent dose adjustments based on
growth velocity, head circumference, and serum IGF-I. ‡Some evidence demonstrates that height SDS at the time of puberty is correlated with near-adult height (110). Therefore, beginning
GH treatment when growth failure is ﬁrst identiﬁed (so that height is normalized by pubertal onset) may be warranted.
FDA, Food and Drug Administration; GH, growth hormone; SDS, standard deviation score.
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one group has suggested performing brain magnetic resonance
imaging (MRI) screens prior to beginning GH therapy (91, 117).
Prior to therapy initiation, a molecular test should be
performed to identify pathogenic variants. For those with gene
variants associated with a high risk of myeloproliferative disorders,
the GH treatment decision should be carefully discussed with
parents and either deferred until after the age of 5 years or begun
with appropriate surveillance prior to 5 years of age (118, 119).

Cognitive/developmental
Annual developmental screening should be conducted with
neuropsychological testing if screening results are abnormal.
Early intervention programs and individualized education
strategies should assess and address issues. Special education,
speech therapy, physical therapy, and/or occupational therapy
may be required in patients with learning issues, language
difﬁculties, and difﬁculties with gross and ﬁne motor skills (1,
12). Consistent evaluation of hearing loss is necessary to improve
hearing management and to reduce its effects on children with
developmental disabilities (60).

Cardiovascular
When NS is ﬁrst diagnosed, an electrocardiogram and an
echocardiogram are recommended to diagnose cardiac defects
and CHD as early as possible (16). Treatment for cardiac-related
conditions tends to be the same as would be used for the general
population (1). Importantly, PS treated with percutaneous
valvuloplasty has a higher reintervention rate in individuals
with NS than in those without due to the dysplastic
pulmonary valve observed in NS (16). In these cases, surgical
valvotomy, which seems to be equally efﬁcacious in individuals
with and without NS, may be required (16). Additionally, there is
a poor prognosis associated with HCM in infants presenting
with congestive heart failure before the age of 6 months (31% 1year survival) (120). Recently, inhibition of mitogen-activated
protein kinase kinase, or MEK, was reported to reverse this
progressive myocardial hypertrophy in two infants (121).

Transition and multidisciplinary care

Because individuals with NS can experience multiple
bleeding disorders, clinical evaluations should be performed at
diagnosis and hemostatic coverage in symptomatic individuals
must be considered prior to any surgery (122). Treatment for
bleeding issues in NS must be based on the speciﬁc hematologic
anomalies identiﬁed in the individual. Aspirin and aspirincontaining medications should be avoided (1).
For individuals with NS who display speciﬁc variants (primarily
codon 61 and p.T731 PTPN11 variants or p.T581 KRAS variants)
that confer a high risk of myeloproliferative disorders/juvenile
myelomonocytic leukemia, surveillance via yearly physical
examination is recommended between birth and 5 years of age.
An assessment of spleen size and a complete blood count with
differential should be performed every 3 to 6 months (118). For all
other individuals with NS and non–high-risk or unknown gene
variants, no routine surveillance has been recommended, but
practitioners should maintain an increased awareness and low
threshold for investigating new potential tumor-related symptoms,
including new-onset seizures, headaches, and petechiae (118).

NS is a genetically and phenotypically heterogeneous
condition. Therefore, an accurate diagnosis and appropriate
care can be difﬁcult to obtain, particularly during the
transition period between pediatric and adult health care
systems. Most of the comorbidities of NS that occur during
childhood require follow-up through adulthood. These include,
but are not limited to, cardiac and musculoskeletal defects;
bleeding disorders and tumor predisposition; lymphatic
problems; and cognitive, behavioral, and mental health
issues (2).
It is particularly important to address the cardiac issues that
arise in adults with NS. Although cardiac interventions may be
undertaken during pediatric care, many individuals will require
additional interventions in adulthood. One-third of adults with
NS have ongoing cardiac issues that require the use of
pacemakers, deﬁbrillators, or drugs for heart failure or
arrhythmias (2). Adult CHD centers and guidelines published
by the American Heart Association provide best practices for
managing the transition of adolescents with CHD to
adulthood (123).
Clinical neuropsychological evaluation of the cognitive,
adaptive, and psychological domains of functioning should
extend from childhood through the transition phase in
individuals with NS (12). Adults with NS may also experience
social and interpersonal issues, which can lead to anxiety,
depression, and lower overall life satisfaction (1, 17). Ideally, a
multidisciplinary team composed of geneticists, cardiologists,
endocrinologists, and behavioral and mental health experts will
be involved in a coordinated transition. Management guidelines,
the information provided here, and involvement with patient
support groups may also help during the transition and
through adulthood.

Genitourinary

Turner syndrome

A baseline kidney ultrasound should be performed at
diagnosis. Orchiopexy should be performed by the age of 1
year if testicles remain undescended at that time (2).

TS results from complete or partial loss of the second X
chromosome in females (106). The prevalence of TS is 1 in every

Coagulopathies/malignancy
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outcomes, altered lipid proﬁles, renal abnormalities,
cardiovascular abnormalities, or cognitive functioning;
however, other studies have failed to consistently reproduce
these ﬁndings (21, 126–130). As a result, genetic testing to
determine the X chromosome parent-of-origin in individuals
with TS is not currently recommended.

2000 to 2500 live female births (106). Individuals with TS display
an array of clinical features including short stature, primary
ovarian failure, cardiac anomalies, and neurodevelopmental
difﬁculties. Multinational consensus guidelines for the
diagnosis and management of women with TS have been
published (25).

Cardiovascular

Features

Cardiac defects (Table 1) are seen in approximately 50% of
individuals with TS and may contribute to early morbidity (25,
106, 131–133). An elongated transverse aortic arch, observed in
nearly 50% of cases, may not always be clinically relevant on its
own but may reﬂect abnormalities in the aortic wall, indicating
an increased risk for complications such as aortic dilation and
subsequent dissection (20). In general, left-sided cardiac defects
are associated with an increased risk of aortic dissection,
aneurysm, and sudden death (23, 134). The proposed
mechanism underlying aortic aneurysm in individuals with TS
is the increased synthesis of matrix metalloproteinases (and
decreased synthesis of their inhibitors), which degrade collagen
and elastin, thereby thinning and weakening the aortic wall (22,
134). Bicuspid aortic valve occurs 30 to 60 times more frequently
in individuals with TS than in the overall female population and
may be an independent predictor of TS (25). Although cardiac
problems are seen in all individuals with TS, they may be more
severe in association with the 45,X karyotype or speciﬁc copy
number or X chromosome variants (135, 136).

Clinical presentation of TS can be highly variable depending
on age and whether a patient displays complete versus partial Xchromosome loss or has 45,X monosomy versus mosaicism.
Prenatal ﬁndings may include nuchal translucency, cystic
hygroma, left-sided obstructive cardiac anomalies, or renal
abnormalities. These features are not diagnostic for TS but are
highly suggestive and mandate postnatal karyotyping,
chromosomal microarray, and/or sequencing-based analysis
(106, 124). Other symptoms observed in infancy, including
webbed neck, lymphedema, and coarctation of the aorta, also
indicate a requirement for genetic testing (27). Characteristic
features observed in individuals with TS can be found in Table 1.
Up to 95% of individuals with TS exhibit short stature (24).
Approximately two-thirds of the height deﬁcit can be attributed
to haploinsufﬁciency of the short stature homeobox (SHOX)
gene, which encodes a transcription factor mainly expressed by
osteogenic cells (24, 125). Left untreated, individuals with TS
achieve adult heights of approximately 143 cm (~20 cm shorter
than the average for the general female population) (Figure 3)
(24, 104, 105). It has been suggested that growth deﬁcit severity
is related to X-chromosome haploinsufﬁciency and possibly to
genomic imprinting impacted by the parental origin of the
missing X chromosome, although these ﬁndings have been
inconsistent across studies (24, 106).
While individuals with TS display some similar
characteristics to those with NS, particularly in the fetal and
neonatal periods, TS affects only females and has an entirely
different underlying genetic basis. Further, individuals with TS
present with more left-sided cardiac defects and an increased
prevalence of renal abnormalities. Finally, individuals with TS
tend to exhibit primary hypogonadism which causes both
amenorrhea and infertility.

Puberty
TS is associated with pubertal delay and ovarian insufﬁciency
(Table 1) (106, 137). While spontaneous puberty has been
reported in up to one-third of individuals with X-chromosome
mosaicism, most females with TS will require pubertal induction
with replacement sex hormones (23, 106).

Renal
Congenital renal abnormalities (Table 1) occur about nine
times more frequently in individuals with TS than in the general
population (27, 106, 138).

Metabolic
Many individuals exhibit metabolic issues, including obesity,
glucose intolerance, and type 2 diabetes (26, 106, 139). Metabolic
factors, including perihepatic and pericardial fat thickness, may
also predict increased risk for cardiac problems in individuals
with TS (140).

Other comorbidities
Besides short stature, TS is accompanied by several
comorbidities including abnormalities of the cardiovascular,
metabolic, gastrointestinal, genitourinary, and nervous
systems. Some groups have attributed the diversity of
phenotypic features seen in individuals with TS to the parental
origin of the X chromosome. Individual reports have indicated a
parent-speciﬁc effect of X-chromosome inheritance on growth
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Cognitive/developmental
Although individuals with TS typically have a normal IQ,
about 10% present with an intellectual disability (106, 141, 142).
Girls with TS tend to have challenges with executive functioning
and motor coordination; ASD and ADHD are also common
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FIGURE 3

Growth curves for patients with TS. Heights of individuals with TS at the start of GH treatment (open symbols) and at ﬁnal height (solid symbols).
Heights from a reference TS population are shown with solid lines and overlaid on normative growth curves from the National Center for Health
Statistics (shaded area), with normative 50th to 90th percentiles in dark shading and normative 10th to 50th percentiles in light shading.
Reprinted from J Pediatr, 132(2), Rosenfeld RG, et al. 319-24, ©1998 Mosby, Inc. with permission from Elsevier. GH, growth hormone; TS, Turner
syndrome.

(106, 142, 143). Individuals with TS tend to have average to
above-average reading and verbal abilities but fall short of ageappropriate averages in overall comprehension and visuospatial
skills, including mathematics and processing speed (142, 144).
Individuals also show impaired social functioning, speciﬁcally in
the areas of facial recognition, fear processing, and interpreting
social cues (141, 142). These ﬁndings may possibly be attributed
to abnormal structural and connective differences in the brains
of individuals with TS (145–148). It has also been suggested that
differences in X-linked parent-of-origin and imprinting effects
inﬂuence neurocognitive outcomes in patients with TS, although
additional studies are needed (149–151).

Frontiers in Endocrinology

Auditory
Ear and hearing issues are present in about 19% of
individuals with TS and include external ear abnormalities,
frequent otitis media, cholesteatoma, and conductive or
sensorineural (in adults) hearing loss (27, 106, 152). Ear and
hearing issues may require the placement of myringotomy
tubes (25).

Oncologic
Individuals with TS also appear to be at a slightly increased risk
for the development of certain neoplasms (e.g., meningiomas,
melanomas), perhaps due to an increased frequency of copy
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(25). Noninvasive prenatal testing of maternal cell-free DNA is
currently not routinely recommended, as it does not adequately
predict TS or detect mosaicism (157, 158). Regardless of the
prenatal testing performed, postnatal karyotyping is always
required to conﬁrm a diagnosis of TS (25, 106).
Other clinical characteristics that should prompt testing for
TS include short stature, left-sided obstructive cardiac
abnormalities, renal anomalies, multiple nevi, frequent bouts
of otitis media, hearing loss, TS-speciﬁc neuropsychological
issues, and delayed sexual development (25, 106, 156).
Despite the variability of phenotypes among individuals with
TS, standard karyotyping can detect TS with up to 95%
conﬁdence (25, 159). In cases where TS is strongly suspected
but the result of the ﬁrst karyotype is normal, additional tissues
or more metaphase spreads may need to be analyzed or
chromosomal microarrays used to detect either mosaicism or
complete chromosome loss (106, 141).
Early diagnosis is key; patient outcomes are improved with
timely initiation of care. In particular, earlier initiation of GH
may result in increased height velocity and adult height
outcomes or may narrow the height gap at an earlier age (25,
27, 160). Studies have revealed that up to 30% of TS diagnoses
may not be made until adulthood (161). Additionally, short
stature alone often does not prompt appropriate testing for
genetic disorders in girls. However, improved diagnostic
guidelines and screening procedures are decreasing this
diagnostic delay (27, 106, 161). Education of providers on the
clinical signs and symptoms of TS may help to ensure early
diagnosis and care for TS-associated comorbidities (25).

number variants, autosomal aneuploidies, and chromosomal
instabilities (25, 128, 135). Some individuals (approximately 10%
of cases) with TS harbor Y chromosome sequences; these
individuals display an increased prevalence of gonadoblastoma
and germ cell tumors. The presence of Y chromosome genetic
material is a consideration for gonadectomy (23, 25).

Autoimmune
Individuals with TS may be up to twice as likely as the
general female population to develop certain autoimmune
disorders, including Hashimoto thyroiditis, vitiligo, juvenile
idiopathic arthritis, celiac disease, and inﬂammatory bowel
disease (27, 106, 153). The mechanisms underlying the
development of these diseases remain unclear but may be
related to X-chromosome haploinsufﬁciency (153, 154).

Diagnosis
The genetics underlying TS encompass several different Xchromosome anomalies, including 45,X (55%) and Xchromosome mosaicism (25%). About 20% of individuals with
TS will have a more complex karyotype, including deletion of the
short arms of the X chromosome or ring X chromosome (155).
About 75% of all cases are thought to originate with the sperm
missing an X chromosome (127, 156).
TS should be suspected in any female infant who presents
with suggestive fetal or postnatal features (141). Amniocentesis
or chorionic villous sampling may reveal TS in a fetus (Figure 4)

FIGURE 4

Genetic testing ﬂowchart for TS. A diagnosis of TS can be suspected based on fetal tests, including amniocentesis and chorionic villous sampling.
However, all diagnoses require postnatal conﬁrmation via 30-cell karyotyping to identify defects such as a missing X chromosome, the presence of
a Y chromosome, or other X chromosome problems (eg, deletions, ring chromosomes, isochromosomes, translocations). In cases where TS is
strongly suspected based on clinical features but the ﬁrst karyotype comes back normal, additional karyotyping should be performed using
additional tissues and/or more metaphase spreads. FISH can also be used to detect X-chromosome mosaicism. Cases that present as 45,X/46,XY
and 45,X should undergo additional FISH for the DYZ3 locus, which will detect the presence of Y-chromosome material. If Y-chromosome material
is present, the risk for gonadoblastoma is elevated and patients should be referred to a specialist for consultation for gonadectomy. Adapted from
Ackermann A, Bamba V. J Clin Transl Endocrinol 2014;1:61-5. FISH, ﬂuorescence in situ hybridization; TS, Turner syndrome.
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menstruation. Transdermal estradiol, which is associated with
decreased thromboembolic and carcinogenic risk relative to
other routes of administration, is the preferred starting
method and should be initiated at a low dose (3-7 µg/day) at
about 11 years of age and slowly increased to the full adult dose
(25-100 µg/day) over the course of approximately 2 years (23, 25,
167, 168). Doses should be increased by between 25% and 100%
every six months to achieve the full adult dose in the
recommended time frame (25). Estrogen treatment also has
beneﬁcial effects on bone mineral density, fasting glucose, and
cholesterol levels (106, 139). Progestin should be started after
about 2 years of estrogen therapy or once breakthrough bleeding
has occurred (25, 106).
Some studies have suggested that induction of puberty can
promote earlier epiphyseal closure, thereby compromising adult
height outcomes (169). However, the results of many of these
studies are underpowered and inconclusive. Therefore, timing of
pubertal induction should be an individual decision made in
careful consultation with providers who have experience treating
TS and considering growth potential, bone age, and psychosocial
aspects of undue pubertal delay.
Levels of follicle-stimulating hormone and luteinizing
hormone should be evaluated before beginning pubertal
induction to conﬁrm the presence of hypergonadotropic
hypogonadism (106). Individuals with TS and normal ovarian
function should receive counseling about their options for
fertility preservation as early as possible (106).

It has been proposed that screening for TS be added to NBS
programs. However, karyotyping can be expensive, timeconsuming, and labor-intensive, as it requires living cells.
Pyrosequencing, real-time polymerase chain reaction, and
whole exome sequencing, which are DNA-based, have all been
proposed as alternative NBS methods (25, 124).

Treatment
Growth
Individuals with TS and short stature can receive GH
replacement therapy to promote catch-up growth. Treatment
with GH is recommended to start around 4 to 6 years of age
(earlier if growth failure is present) and may result in a height
SDS gain of up to 1.5 (Table 3 and Figure 3) (25, 162–164). In
some instances, individuals who start GH at a younger age may
display better height outcomes and improved body composition
and bone growth (25, 27, 106, 107, 160, 164). GH treatment is
associated with an average height gain of 1 cm per year based on
randomized studies, and improved height gain has been
reported in some observational trials (25, 104, 165, 166).
Once GH treatment is started, IGF-I concentrations should
be monitored at least annually and should ideally be maintained
at or below an SDS of +2. Upon testing, if the IGF-I SDS is
greater than +3, the GH dose should be decreased, and if the SDS
is between +2 and +3, the provider should use their best clinical
judgment regarding dosing (25). Girls with TS on GH therapy
are at increased risk for intracranial hypertension, slipped capital
femoral epiphysis, and worsening of scoliosis, presumably due to
accelerated growth rates (25, 106).
Individuals with TS are at a higher risk of metabolic
disorders associated with insulin resistance. These disorders
may be transiently exacerbated during GH treatment with
resolution after treatment completion (141). Plasma glucose
and hemoglobin A1c should be measured annually beginning
around 10 years of age. Girls with TS should also receive
counseling to highlight the importance of a healthy diet and
physical activity (26, 106).
In addition to GH, non-aromatizable androgens, such as
oxandrolone, have been used to stimulate height velocity in
individuals with a late diagnosis of TS or with concern for
extremely short height outcome (163), although this practice is
more common in Europe than in the US. Current guidelines
suggest adding treatment with oxandrolone at ≥10 years of age
(25). Delayed breast development, mild excess body hair, and
voice deepening have been noted in some oxandrolone-treated
patients, emphasizing the need to delay treatment until later in
childhood and to keep doses below 50 mcg/kg/d (25).

Cardiovascular
Cardiac abnormalities are detected using echocardiography,
MRI, or magnetic resonance angiography (MRA) (23, 133, 170).
Some abnormalities, including an elongated transverse aortic
arch and partial anomalous pulmonary venous return, can only
be observed via MRI/MRA. Current guidelines recommend
echocardiographic evaluation of newly diagnosed girls with TS
irrespective of their cardiac risk status and regular monitoring
thereafter to detect arrhythmias (25, 106). MRI/MRA should be
considered as soon as the procedure can be performed without
sedation; however, implementation can be limited by difﬁculties
in obtaining insurance approval (20). Vascular issues, such as
coronary artery disease, are also common among individuals
with TS and can be detected using computed tomography
angiography or cardiac MRI (133, 170).
Treatment for cardiac issues depends on the severity of the
abnormality and on other associated risk factors (e.g., obesity,
hypertension). Most individuals are stratiﬁed by their overall
cardiac risk level and screened at regular intervals per the current
consensus guidelines (25, 136). It is recommended that girls in
the high-risk category avoid highly competitive sports and
intense weight training (106). For cardiac abnormalities such
as aortopathies and left-sided obstructive lesions, cardiac surgery
is usually indicated (25, 171). Individuals with TS who undergo
cardiac surgery experience increased morbidity and lengthier

Puberty
Many individuals with TS will require treatment with
estrogen and progestin to induce breast development and
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display lower TRAQ scores than their unaffected peers and may
require additional support during the transition process (173).
Current guidelines for the management of TS recommend a
planned and staged process for the transition from pediatric to
adult health care systems. Coordination between pediatric and
adult providers is required to ensure continuity of care. It is
recommended that providers use available transitional tools,
including the TS Pediatric to Adult Care Transition Toolkit4, to
support these individuals and to help them identify the role of
each member of their care team (25).
The importance of multidisciplinary treatment extending
from childhood through adulthood cannot be overemphasized.
Clinics, patient support groups, and even telemedicine health
visits may help to guide individuals with TS as they make healthy
lifestyle choices related to diet, exercise, and fertility planning
(25). Dedicated multidisciplinary clinics aimed at supporting
individuals with TS during and after the transitional period can
also increase identiﬁcation and treatment of comorbidities in
adults (25, 174). A multidisciplinary care team for adults with TS
will ideally include specialists in genetics, cardiology,
reproductive endocrinology, audiology, and psychology/
neuropsychology. Multidisciplinary care and regular
monitoring are especially important in pregnant women with
TS, as pregnancy is an additional risk factor for cardiac issues
such as heart disease and aortopathy (23, 25, 106).
Comprehensive care of individuals with TS from childhood to
adulthood will ensure that they achieve their full potential and
optimal quality of life.

hospital stays but do not display increased peri-operative
mortality relative to patients without TS (171). Pregnancy is
associated with an increased risk of cardiac-related death due to
aortic dissection in individuals with TS; therefore, alternatives
including adoption and surrogacy should be considered, even if
fertility indices are normal. Assisted fertility should be
undertaken with caution in a center experienced in this
population. If pregnancy does occur (either spontaneously or
through in vitro fertilization), regular cardiac assessments,
including echocardiography, electrocardiography, and MRI,
should be performed throughout the pregnancy and the
postpartum period (20, 23). Implantation of multiple fertilized
embryos may result in multiple gestation with an increased risk
of cardiac complications (23).

Neurologic/cognitive
To ensure prompt recognition and treatment of TSassociated neurocognitive deﬁcits, some publications suggest
yearly neurodevelopmental evaluation for at least the ﬁrst
three years of life (25, 142). Identiﬁcation of issues during
these screenings can lead to prompt intervention and
improved outcomes. For example, cognitive behavioral therapy
and classroom modiﬁcations can help improve learning
outcomes related to executive functioning (106). ADHD
medications can also have a positive effect on academic
achievement; however, medical history and cardiac health
should be considered before initiating treatment with
stimulant medications (106, 142). Counseling should also be
made available to individuals with TS, as they frequently
experience low self-esteem, anxiety, and depression (106, 142).

Prader-Willi syndrome
Prader-Willi syndrome (PWS) is a rare genetic disorder that
occurs in approximately 1 in every 10,000 to 20,000 individuals
(31, 35, 36, 38, 39). The syndrome affects males and females
equally (175) and is the most common known genetic cause
of obesity (29, 35, 36, 39). The disorder is characterized by loss of
paternally expressed genes in the imprinted region of
chromosome 15q11-q13. Mechanistically, this can result from
deletions within the paternal chromosome 15, maternal
uniparental disomy 15 (UPD 15; inheritance of both copies of
chromosome 15 from the mother and none from the father), or
(infrequently) imprinting defects (38, 39, 176–180).

Transition and multidisciplinary care
Appropriate transitioning of individuals with TS from
pediatric to adult health care providers is critical to ensure
continuity of care. Individuals with TS tend to visit their
providers with decreasing frequency as they age (typically due
to competing social, educational, and ﬁnancial priorities) and
may be lost to follow-up in their adult years. These individuals
therefore do not receive the recommended screening and care
for disease-associated comorbidities, leading to poor health
outcomes (25). Notably, adequate medical care following the
transition occurs in only 3.5% of individuals with TS (172).
The Transition Readiness Assessment Questionnaire (TRAQ)
5.0, a self-assessment that examines patients’ health knowledge
and literacy (including managing daily activities, keeping
appointments, and managing medications), may be an
important tool for providers to assess an individual’s readiness
prior to their transition to adult health care (25, 172). A
comparative study assessing individuals with TS and individuals
without a chronic condition revealed that participants with TS
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years of age (38, 190). Individuals with PWS caused by a
chromosome 15q deletion may be more likely to experience
seizures than those with PWS caused by UPD, due to the
deletion of a cluster of gamma-aminobutyric acid subunit
genes on chromosome 15, which are involved in proper
neuronal development and functioning (190).
Central and/or primary hypogonadism and pubertal delay is
present in nearly all individuals with PWS and is commonly
associated with infertility (38, 39). Hypogonadism typically
presents as genital hypoplasia and cryptorchidism (31, 33, 36,
181, 191, 192).

Features
Clinically, infants with PWS are characterized by severe
hypotonia and failure to thrive due to feeding difﬁculties. In
utero, they are typically within a normal size range but may
exhibit polyhydramnios (181) and decreased movement due to
fetal hypotonia (29, 30, 36, 38, 39). In infancy, persistent
hypotonia is accompanied by feeding problems, lethargy, and
poor suck, often resulting in low body weight (33, 35).
Infant length is typically normal in the ﬁrst few months of
life but falls below normative growth within the ﬁrst year (182).
Short stature becomes particularly apparent during puberty,
with the median height for individuals with PWS falling below
the ﬁfth percentile for unaffected individuals (33)
(Figures 5A, B).
The feeding difﬁculties noted in infancy give way to
hyperphagia (excessive eating accompanied by lack of satiety)
in childhood and can lead to obesity by 2 to 4 years of age if not
controlled (Figures 5C, D) (30, 31, 175, 183). It is hypothesized
that hypothalamic dysfunction, increased production of the
hormone ghrelin (which stimulates appetite), and the
decreased activity and caloric requirements observed in
individuals with PWS lead to the onset of obesity (31, 33, 35,
36, 38, 39, 184).
PWS is characterized by several distinctive facial features,
which are listed in Table 1. Individuals with PWS also exhibit
decreased saliva production, leading to dry mouth, caries, and
other dental issues (40, 185).

Cognitive/developmental
Individuals with PWS may present with signiﬁcant cognitive
impairments, including delayed development of language,
cognitive, and motor skills (38); however, most exhibit mild
learning and/or intellectual disabilities, with an average IQ score
around 65 (30, 33, 39). The severity of these impairments may
vary depending on molecular genetic class (Table 4). While fullscale IQ scores are low across PWS subtypes, verbal IQ scores are
signiﬁcantly lower in individuals with deletions than in those
with UPD 15 (194, 197). Conversely, individuals with UPD 15
are more likely to exhibit signs of ASD or psychotic illness,
possibly due to the duplication of several key imprinted and
maternally expressed genes in the 15q11-q13 region, including
UBE3A and ATP10A (33, 36, 39, 180, 196, 198). Overall, 12% to
41% of children with PWS have ASD (199).
Behavioral issues, including frequent temper tantrums,
stubbornness, and manipulative behaviors, are seen in up to
90% of individuals with PWS but may vary in type or severity
between the PWS molecular genetic classes (38, 193). Many
children exhibit obsessive-compulsive symptoms such as
repetitive questioning and checking behaviors. Others exhibit
compulsive food-seeking, hoarding, or self-harming behaviors,
such as skin-picking (39, 195, 196, 200). Many compulsive
behaviors and psychological issues appear to be worse in
individuals with chromosome 15q deletions versus those with
UPD 15 (Table 4) (193, 195). Individuals with PWS often prefer
solitary activities and may exhibit signs of anxiety and
depression (196).

Other comorbidities
Metabolic/endocrine
Individuals with PWS are prone to hypothyroidism, central
adrenal insufﬁciency, body composition changes, and obesityassociated problems, including type 2 diabetes (38, 39, 186).
Individuals with PWS and obesity or diabetes are more likely to
experience cardiovascular disease, venous thromboembolism,
myocardial infarction, and mortality (187, 188). Individuals
with PWS and obesity exhibit increased insulin sensitivity and
decreased fasting insulin levels relative to individuals with
obesity without PWS, suggesting differences in insulin
metabolism and regulation of fat patterning (189). Further, the
presence of obesity in individuals with PWS is associated with
increased rates of metabolic syndrome (relative to individuals
with PWS without obesity), deﬁned by at least three of the
following characteristics: high blood glucose, low high-density
lipoprotein cholesterol levels, increased waist circumference,
high triglyceride levels, and high blood pressure (41).
Hypothalamic insufﬁciencies can predispose those with PWS
to seizures and hypogonadism (36). Seizures occur in 10% to
20% of the PWS population, most often developing before 6
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Sleep
Many individuals with PWS exhibit sleep issues, including
altered sleep patterns and obstructive or central sleep apnea (39,
185, 201). These individuals tend to have decreased oxygen
saturation, rapid onset of REM sleep, and increased daytime
sleepiness (which may impact behavioral issues), particularly in
late childhood and adulthood (30, 38, 202, 203). Obesity is a
frequent underlying cause of sleep disturbances; however,
individuals with PWS with or without obesity tend to
experience sleep problems (201, 204). One explanation for this
ﬁnding may be the decreased muscle mass and tone seen in
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FIGURE 5

Standardized curves for height and weight of non-GH-treated patients with PWS. (A, B) Standardized curves for height of non-GH-treated
males (A) and females (B) with PWS. Heights of individuals with PWS are shown with solid lines and overlaid on the normative percentile ranges
(shaded area) with normative 97th to 50th percentiles in dark shading and 50th to 3rd percentiles in light shading. Adapted from Butler MG et al.
Pediatrics 2015;135(1):e126-35. (C, D) Standardized curves for weight of non-GH-treated males (C) and females (D) with PWS. Weights of
individuals with PWS are shown with solid lines and overlaid on the normative percentile ranges (shaded area) with normative 97th to 50th
percentiles in dark shading and 50th to 3rd percentiles in light shading. Adapted from Butler MG et al. Pediatrics 2015;135(1):e126-35. GH,
growth hormone; PWS, Prader-Willi syndrome.
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TABLE 4 Phenotypic correlation with molecular genetic class in
PWS.

Molecular
Genetic Class

Characteristics

15q11-q13 deletion

•More severe verbal and performance IQ impairments

underlying PWS genetic subtype, which is correlated with
varying clinical features and severity (Table 4) (29, 39, 193, 194).
Approximately 60% of PWS cases are caused by a typical
15q11-q13 deletion (either a larger type I or a smaller type II
deletion) in chromosome 15. Type I and type II deletions involve
the same distal 15q breakpoint (BP3) but different proximal
15q11-q13 breakpoints (BP1 or BP2) and result in deletions of
approximately 6 Mb and 5.5 Mb, respectively (180). Notably,
several key neurodevelopmental genes are removed in type I but
not in type II deletions; thus, individuals with the type I deletion
may exhibit increased developmental delays and neurological
issues relative to those with the type II deletion (39, 193).
However, individuals with both types of deletions tend to have
more severe verbal and performance IQ impairments relative to
those with other PWS molecular subtypes (Table 4) (185, 193,
197). Approximately 35% of PWS cases are due to maternal
UPD 15, while the remaining ~5% of cases are due to imprinting
defects or chromosomal translocations or inversions (180).
Cases of PWS stemming from deletions and UPD 15 are
typically spontaneous and future siblings are unlikely to be
affected. However, if PWS is traced back to an inherited
imprinting defect or a paternally-inherited imprinting center
microdeletion, then the chances of having another child with
PWS could be 50% (31, 38).
A combination of molecular and genetic testing techniques
can pinpoint the underlying cause of PWS and 15q11-q13
expression loss (Figure 6). Historically, testing began with
high-resolution chromosome analysis or, later, DNA
methylation analysis, which would conﬁrm that only
maternally imprinted genes from the 15q11-q13 region were
present (29, 33, 38). Fluorescence in situ hybridization could also
determine whether a deletion or inversion had occurred in
chromosome 15. Currently, high-resolution single-nucleotide
polymorphism chromosomal microarrays can be used to
identify deletion subtypes (type I or type II) and UPD 15
subclasses (35, 36, 180, 209). These subclasses include
segmental isodisomy 15 and total isodisomy 15, which result
from varying numbers and sizes of crossover events during
maternal meiosis. Individuals with PWS and isodisomy 15 are
at risk of secondary genetic conditions if the mother is a carrier
of a disorder-associated recessive gene on chromosome 15. DNA
polymorphism, methylation-speciﬁc multiplex ligationdependent probe ampliﬁcation (210), and whole exome
sequencing analyses can be used to distinguish between UPD
15 and imprinting defects (211). Recently, a streamlined
approach for molecular diagnosis of PWS has been reported
that combines DNA methylation, copy number status, and
exome sequencing into one assay (208).
Early diagnosis is crucial to minimize many of the
comorbidities associated with PWS. Unfortunately, children
may be diagnosed anywhere between 18 days and 8 years of
age (37, 185), as clinical features can be subtle in presentation
and can change dramatically with age (30). In some cases, the

•Higher pain threshold
•More likely to experience seizures
•Worse compulsive and self-injurious behaviors
•Increased sleep disturbances
•Increased need for special feeding techniques
•Hypopigmentation
•Lower waist-to-hip ratio, higher hip circumference
Type I deletion

•Increased behavioral and compulsive problems
•Poorer academic performance
•Increased developmental delays
•Increased neurologic issues

Type II deletion

•Better adaptive behavior and social skills relative to
type I deletion or maternal UPD

Maternal UPD

•Less likely to have typical facial appearance
•Higher verbal IQ
•Milder behavioral problems
•Fewer compulsive behaviors
•More likely to show signs of ASD
•Increased psychiatric illness and bipolar disorder
•Better visual memory
•Increased anxiety

ASD, autism spectrum disorder; PWS, Prader-Willi syndrome; UPD, uniparental disomy.
Sources: (33, 35, 38, 189, 190, 193–196).

PWS, which could lead to respiratory distress or collapse during
sleep-associated relaxation (33).

Skeletal
Orthopedic problems are also prevalent in individuals with
PWS. Approximately 10% and 40% of individuals with PWS will
exhibit hip dysplasia and scoliosis, respectively, in infancy and
early childhood (38, 39). Scoliosis has been suggested to be a
comorbidity for respiratory issues including severe sleep apnea
(205). Osteoporosis and osteopenia are also common and can
increase the risk for stress fractures (39, 206).

Diagnosis
PWS should be considered in most cases of severe infant
hypotonia, failure to thrive, and poor suck and can be clinically
diagnosed using a scoring system developed in the 1990s. This
system assigns points to major and minor clinical features and
establishes point thresholds for positive diagnoses at various ages
(30). However, a molecular test is typically required for
diagnostic conﬁrmation, as other genetic disorders, including
X-chromosome abnormalities and Angelman syndrome, can
cause similar phenotypes to PWS (36, 38, 39, 185, 207).
Critically, molecular genetic testing can help to determine the
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FIGURE 6

Genetic testing ﬂowchart for PWS. Testing should begin with a DNA methylation analysis, to conﬁrm that only maternally imprinted genes from
the 15q11-q13 region are present. High-resolution SNP arrays, FISH, MS-MLPA, and/or ddPCR can be used to detect chromosome 15 deletion
subtypes. SNP arrays can also be used to detect maternal UPD 15 subtypes or imprinting center defects. A streamlined approach combining
DNA methylation, copy number analysis, and exome sequencing has also been reported for molecular diagnosis of PWS (208). Adapted from
Butler MG, Duis J. Front Pediatr 2020;8:154. Chr, chromosome; ddPCR, droplet digital polymerase chain reaction; FISH, ﬂuorescence in situ
hybridization; MS-MLPA, methylation-speciﬁc multiplex ligation-dependent probe ampliﬁcation; PWS, Prader-Willi syndrome; SNP, single
nucleotide polymorphism; UPD 15, uniparental disomy 15; WES, whole-exome sequencing; WGS, whole-genome sequencing.

or enteric tube feeding to address poor suck and decreased
caloric intake, although tube-associated risks including increased
risk of reﬂux and scarring should be considered (181, 215).
Special nipples can also be used to encourage infants to begin to
feed on their own (38).
Later, hyperphagia can lead to weight gain, if not controlled.
The earlier weight gain is addressed, the better the outcomes will
be (216). Children with PWS beneﬁt from highly regimented
feeding schedules, including caloric restriction and dependable
eating times, the latter of which can minimize food-related
anxiety (31, 38, 175). Parents should also take care to
eliminate food-oriented rewards and punishments. A dietitian
should be consulted to ensure that proper nutritional balance is
being maintained under restricted conditions (31, 39, 184, 217).
Individuals should be supervised closely to prevent foodstealing, and environmental controls, such as locking
refrigerators and cabinets, may be necessary. An exercise
regimen should also be highly encouraged (184). Gastric
bypass is not recommended for individuals with PWS, as it
does not address the lack of satiety and the drive to overeat (38).
Several agents are currently in clinical trials for the treatment
of hyperphagia in PWS. The anti-epileptic drug topiramate has
had a signiﬁcant effect on disordered eating in several small
studies (218, 219) and is also recommended for the treatment of
skin-picking, a common obsessive-compulsive manifestation

need for genetic testing should be immediately evident based on
infant hypotonia and failure to thrive with poor suck. However,
the lack of rare disease expertise and awareness along with poor
accessibility to genetic testing may limit the ability of physicians
to order the correct tests and properly diagnose infants
(185, 212).
In the US, NBS is regulated at the state level and no states
currently test for PWS. However, adoption of molecular testing
for PWS in newborns, whether as a part of NBS or due to speciﬁc
perinatal characteristics including decreased fetal movement,
will lead to younger age at diagnosis, lower burden on the
healthcare system, and decreased cost (213). Improved
education and outreach efforts to raise awareness of the
beneﬁts of PWS screening as part of NBS programs will be
required before this can become a reality, but preliminary studies
are promising (214).

Treatment
Nutrition/obesity
Multiple treatment regimens are required to address the
primary manifestations and comorbidities associated with PWS.
One of the most immediate concerns is the regulation of
nutritional intake. Infants with PWS may require nasogastric
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can be helpful to stimulate development of secondary sex
characteristics and to ameliorate psychosocial aspects of
pubertal delay. However, sex hormone treatment is
controversial, as testosterone can exacerbate behavioral
problems in males and estrogen can lead to increased stroke
risk and menstruation-associated hygiene concerns in females
(38, 39). This risk potential needs to be evaluated in the context
of delayed puberty requiring sex steroid replacement (191, 192).

seen in individuals with PWS (175). Several additional
therapeutics with various mechanisms of action, including
carbetocin, setmelanotide, diazoxide choline controlled release,
unacylated ghrelin, tesofensine/metoprolol, and several
glucagon-like peptide 1 receptor agonists, are currently in
clinical trials for the treatment of hyperphagia and obesity (42,
220–223). Transcranial direct current stimulation trials in
individuals with PWS have also shown promise in the
treatment of hyperphagia (224, 225).

Skeletal
Growth/endocrine

Spinal deformities, including scoliosis, may result from the
severe hypotonia characteristic of individuals with PWS (205).
Some studies have indicated that GH treatment may contribute
to worsening scoliosis in PWS; however, later studies failed to
support these ﬁndings (38, 108). Physical therapy focused on
core strengthening can be helpful in reducing or avoiding spinal
deformities. In younger patients already presenting with a spinal
curve, serial casting may be used to guide the spine into a
straighter position. Bracing can be helpful in those with minor
spinal curves who are too old for casting or in children who are
not old enough to undergo corrective surgery (205). Surgery is
typically recommended only after 12 and 14 years of age in
females and males, respectively. The procedure does come with
some inherent risks including the inadvertent adding-on to the
spinal curve. In some cases, a combination of spinal curvature
and characteristic PWS bone weakness can lead to hardware
pullout or failure, which has disastrous effects (205).

Most individuals with PWS will exhibit GH deﬁciency;
therefore, supplemental GH treatment is critical. GH therapy
is approved in the US for individuals aged ≥2 years with PWS
and documented growth failure and can normalize height
outcomes by 18 years of age (Table 3 and Figures 7A, B) (36,
108, 109). GH treatment can improve many additional PWS
outcomes, including metabolism, body composition, mobility,
behavior, bone density, and development of motor skills (36, 38,
39, 206, 226, 227). Decisions to treat with GH should be made in
consultation with a pediatric endocrinologist with the
understanding that earlier treatment may lead to improved
outcomes (175, 216, 228). Treatment should not be started if
the patient presents with severe obesity, unregulated diabetes,
and/or obstructive sleep apnea (108).
GH treatment increases IGF-I concentrations, which can
lead to adverse events including lymphoid tissue hypertrophy.
Therefore, IGF-I should be consistently monitored in
individuals treated with GH and maintained within a
physiologically normal range (108). Some patients present
with very high IGF-I concentrations even on low doses of GH;
in these patients, treatment should be continued in the interest
of growth and metabolic beneﬁts but should be adjusted so that
the ratio between IGF-I and insulin-like growth factor-binding
protein 3 is maintained at baseline levels (34). In the short-term,
GH therapy may increase a patient’s risk of diabetes, although
this risk is likely offset by its long-term beneﬁcial effects on body
composition (228). Individuals under consideration for GH
therapy should undergo a sleep study to identify obstructive
sleep apnea prior to treatment initiation and periodically
thereafter, as GH may worsen sleep centrally and can also
cause IGF-I-induced adenotonsillar hypertrophy (38, 204). In
severe cases, an otolaryngologist may recommend cessation of
GH treatment until polysomnography results improve (175).

Cognitive/behavioral
Cognitive impairments should be addressed with special
educational planning and speech therapy, if needed (31, 38).
Parents and patients should manage cognitive and behavioral
issues, including obsessive-compulsive tendencies, anxiety, and
depression, with the help of a behavioral specialist, therapist, or
psychologist (175).

Transition and multidisciplinary care
As with the other syndromes discussed in this review, early
diagnosis is essential and can improve outcomes associated with
PWS-related comorbidities. However, appropriate diagnosis can
be difﬁcult due to the complex testing required to identify the
PWS molecular genetic class.
Treatment of individuals with PWS can be especially difﬁcult
during the transition period. While some providers may be
willing and able to care for the patient with PWS from
childhood through adulthood, other adult subspecialists may
be unwilling to take on complex PWS cases. When a transition
from pediatric to adult care is necessary, direct communication
between providers (possibly at a dedicated transitional meeting)
is key to ensure uninterrupted care (230). Care should overlap

Puberty/genitourinary
Cryptorchidism can be treated with human chorionic
gonadotropin or, if that approach fails, surgical intervention
(38, 39, 175). A small study in individuals with PWS and
cryptorchidism reported that 81% of testes descended to a
lower position following treatment with human chorionic
gonadotropin (229). Later, sex hormone replacement therapy
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FIGURE 7

Standardized curves for height and weight of GH-treated patients with PWS. Curves for height (top) and weight (bottom) of GH-treated males
(A) and females (B) with PWS. Heights and weights of GH-treated individuals with PWS are shown with solid lines and overlaid on the normative
percentile ranges (shaded area) with normative 97th to 50th percentiles in dark shading and 50th to 3rd percentiles in light shading. Butler MG
et al. Clin Pediatr (Phila) 2016;55(10):957-974. ©2016, SAGE Publications. Reprinted by Permission of SAGE Publications. GH, growth hormone;
PWS, Prader-Willi syndrome.

endocrinologist, orthopedist, gastroenterologist, psychologist/
psychiatrist, social worker, occupational therapist, and care
coordinator), which can help ensure that routine medical care
for an individual with PWS remains smooth and uninterrupted
and can reduce morbidity for these patients. Having all providers
together in one clinic can also reduce the burden on patients and
their families, as multiple providers can be seen at one time and
place, versus having to make different appointments for different
providers in different locations (234).
The speciﬁc roles for the many members of the PWS
multidisciplinary team are described below. Geneticists should
perform testing to determine the molecular mechanism
underlying speciﬁc cases of PWS and provide counseling on
how these mechanisms may inform recurrence risk in future
offspring, impact treatment for particular genetic subtypes, and
affect disease surveillance (38, 39, 179, 230, 234).
Endocrinologists can address GH deﬁciency (39), provide
information on the beneﬁts and risks of beginning GH
treatment early (230, 234), and counsel patients and parents
on the possibility of pubertal induction with sex hormones.
Endocrinologists should be the point of contact for counseling
on other PWS-associated hormonal issues such as
hypothyroidism, central adrenal insufﬁciency, and diabetes (39,
230, 234). Long term follow up, natural history, and progression
of the disorder should be undertaken by the clinical geneticist.

until all parties (providers, patients, and caregivers) are
comfortable with the transition (175). Patients actively
involved in the transition process are more likely to have
better physical and behavioral health than those who are not
involved (231).
Multidisciplinary care is essential for individuals with PWS,
as they present with a plethora of co-morbidities that all require
specialized care, including routine care or screening in
adulthood for weight control, diabetes, hypertension, sleep
apnea, peripheral edema, heart failure, and behavioral
management (39, 108, 209, 231). Individuals with PWS should
also receive counseling to discuss psychosexual maturation,
pregnancy, and contraception (175).
Up to 20% of transition-age individuals with PWS display
GH deﬁciency. Therefore, it is recommended that individuals
transitioning to adult care undergo GH stimulation testing to
inform treatment strategies during this critical time (232).
Prior to medication management, pharmacogenetic testing
may be considered to determine cytochrome P450 liver
enzyme status, which can inform drug metabolism rates.
PWS molecular genetic class may also impact the response to
medication (233).
Multidisciplinary clinics can meet a real need for patients
with PWS transitioning to adult health care. These clinics bring
together the entire care team (geneticist, dietitian/nutritionist,
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these fears are by no means universal and are not typically
observed in their own clinical practice.
GH treatment in short children demonstrably improves
patients’ physical, social, and emotional quality of life (240).
Further, patient concerns may, in some cases, be balanced by the
desire to achieve the best possible growth outcomes (239).
Current GH treatments are given as daily subcutaneous
injections. However, in recent years, long-acting GH (LAGH)
therapies have been developed that may reduce treatment burden
and increase adherence. LAGH therapies may be patient-preferred
(238), as they require less frequent injections; however, these
molecules may display suboptimal tissue distribution as a result of
the modiﬁcations required to extend their half-life (e.g., PEGylation)
(241). Currently, two LAGH formulations, somapacitan and
lonapegsomatropin, are FDA-approved for use in adult and
pediatric GH deﬁciency, respectively (242). Studies are ongoing to
evaluate the beneﬁt of other LAGH formulations in additional
indications such as TS (243–245).
NS, TS, and PWS are all accompanied by comorbidities that
require a lifetime of monitoring and treatment as described.
Therefore, it is important for individuals with any of these
syndromes to receive care from a multidisciplinary team of
specialists throughout their life span. However, several factors,
including diagnostic delays and a lack of communication among
health care specialists, can complicate the comprehensive care
needed to support patients with these disorders.
It can be difﬁcult for patients to access high-quality care from
multiple specialists, especially if they live in geographically isolated
areas or have ﬁnancial constraints. In today’s increasingly
connected world, telemedicine can be a great option to ensure
that patients consult with all their care providers and to increase
communication between these providers (234).
Here, we present the clinical features and genetics associated
with each disorder, diagnostic techniques, and treatment
methods. We also discuss the importance of multidisciplinary
care and proper, supported transition from pediatric to adult
health care systems with the hope that this discussion will
reinforce best practices when diagnosing and treating patients
with NS, TS, and PWS.

Nutritionists and dietitians help individuals with PWS
manage nutritional intake and develop exercise plans (184).
Syndrome-speciﬁc growth charts, which have been developed
for patients with PWS from 0 to 18 years of age, should be used
to monitor growth and development (109, 182, 235).
Gastroenterologists care for patients with gastroesophageal
reﬂux, swallowing difﬁculties, or gastrointestinal rupture due
to overeating (39, 230, 234).
Speech pathologists can address swallowing difﬁculties and
speech and articulation problems (31, 234). Sleep specialists are
important for managing the high incidence of central and
obstructive sleep apnea in individuals with PWS (175, 230,
234). Orthopedists can help to address hip dysplasia and
scoliosis, with special attention given to skeletal changes that
may occur during GH treatment. Ophthalmologists can help to
address visual deﬁcits or abnormalities, while dentists are
important for managing PWS-associated oral problems,
including caries and gingivitis (230).
Behavioral and neurodevelopmental specialists are
important to address issues including social functioning,
anxiety, compulsive behaviors, and developmental delays (31,
39, 175, 230, 234). Counseling for the family of an individual
with PWS is also key, as the plethora of comorbidities associated
with this syndrome can take a mental and emotional toll on
everyone involved.
Finally, the importance of the care coordinator should not be
understated. Care coordinators may play a variety of roles and
may be responsible for tasks as diverse as helping patients attend
their appointments, improving communication between health
care providers, educating patients and families, and assisting
with insurance issues (234).

Discussion/conclusion
The three syndromes discussed here are genetic disorders
that affect height outcomes and, typically, GH sensitivity
(Noonan syndrome, Turner syndrome) or production (some
cases of Noonan syndrome, most cases of Prader-Willi
syndrome) (Table 1). Although the syndromes may differ in
their phenotypic presentations (Table 1), nearly all patients will
present with short stature and may beneﬁt from GH
supplementation at some point in their lives.
GH treatment may be associated with physical and
emotional challenges. Painful daily injections and fear of side
effects may decrease treatment adherence in a small percentage
of patients (236–238). The doses themselves can also constitute
a burden, as maintaining proper storage, handling, and
reconstitution of the product may be complicated, particularly
during travel (236–238). Some patients report emotional
consequences of daily GH injections, including fear of
injections and feeling different from others because of their
treatment (239). However, the authors of this review note that
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